Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 7 Thoracic 6 Gastrointestinal 5 Genitourinary 4 Sarcoma 3 Head & Neck 3 Breast 3 Gynecologic 2 Plasma cell 1 Other solid neoplasm 1 Other hematologic neoplasm 1 Myeloid 1 Lymphoid 1 Endocrine 1 Dermatologic 1

Conditions

Neurotoxicity Syndromes 1 Lymphoma, B-Cell 1 Cytokine Release Syndrome 1

Interventions

Rituximab 1401 Cyclophosphamide 1305 Vincristine 668 Doxorubicin 587 Etoposide 527 Prednisone 510 Cytarabine 486 fludarabine 469 Methotrexate 445 Dexamethasone 413 fludarabine phosphate 400 Lenalidomide 356 Filgrastim 343 Bendamustine Hydrochloride 282 Radiotherapy 267 venetoclax 260 ibrutinib 258 obinutuzumab 235 Peripheral Blood Stem Cell Transplantation 234 Melphalan 230 Granulocyte Colony-Stimulating Factor 215 Bortezomib 204 Gemcitabine 202 Busulfan 188 Whole-Body Irradiation 187 Mycophenolic Acid 175 Tacrolimus 165 Specimen Handling 162 Magnetic Resonance Spectroscopy 155 Calcium Dobesilate 150

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Contrast Media × Lymphoid × Clear all

NCT05510596 2024-08-09

MR-ICANS

University Hospital, Montpellier

Phase NA Completed

Cytokine Release Syndrome, Lymphoma, B-Cell, Neurotoxicity Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon ⚡